Return Peptide Library
Orforglipron
ALevel 1 evidenceOrforglipron
GLP-1 and incretin receptor agonists
Basic Information
Categories
Incretin mimetics
Overview
Eli Lilly's oral small-molecule GLP-1 receptor agonist was approved by the FDA in 4 of 2026.
Efficacy Rating
GLP-1 Agonist, Oral, Weight Loss
Evidence Level
Grade A
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Dulaglutide
Dulaglutide
AGLP-1 and incretin receptor agonists
Weight loss, metabolic health, FDA-approved
Liraglutide
Liraglutide
AGLP-1 and incretin receptor agonists
Weight loss, metabolic health, FDA-approved
MariTide
MariTide
AGLP-1 and incretin receptor agonists
Bispecific, GLP-1 Agonist, GIPR Antagonist
Retatrutide
Retatrutide
AGLP-1 and incretin receptor agonists
Weight loss, in research, GLP-1
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.